Background: Cognitive-behavioral therapy for insomnia (CBTi) is considered the standard treatment. The internet has proven to be a useful and successful tool of providing CBTi. However, few studies have investigated the possible effect of unguided internet-delivered CBTi (ICBTi) on comorbid psychological symptoms and fatigue.
Methods: Based on a randomized controlled trial, we investigated whether unguided ICBTi had an effect on comorbid psychological symptoms. Adults with insomnia ( = 181; 67% women; mean age 44.9 years [SD 13.0]) were randomized to ICBTi ( = 95) or to an online patient education condition ( = 86) for a nine-week period.
Results: The results from mixed linear modelling yielded medium to large between-group effect sizes from pre- to post-treatment for symptoms of anxiety or depression ( = -0.57; 95% CI = 0.79-0.35) and fatigue ( = 0.92; 95% CI = 1.22-0.62). The ICBTi group was reassessed at a 6-month non-randomized follow-up, and the completing participants had on the average a significant increase (from the post-assessment) on symptoms of anxiety or depression, while the reduction in symptoms of fatigue (on post-assessment) was maintained. However, due to high dropout attrition and no control group data, caution should be made regarding the long-term effects. In conclusion, the present findings show that unguided ICBTi positively influence comorbid symptoms in the short-term, thereby emphasizing the clinical relevance of unguided ICBTi.
Trial Registration: ClinicalTrials.gov identifier: NCT02261272.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096334 | PMC |
http://dx.doi.org/10.1016/j.invent.2018.02.003 | DOI Listing |
Paediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFJ Neurooncol
January 2025
Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA.
Background: Medulloblastoma is the most commonly occurring malignant brain tumor of childhood. Treatment includes a combination of surgery, radiation therapy, and chemotherapy, all of which are associated with cognitive impairments. Despite appreciation of the value of neuropsychological evaluations to assess for cognitive impairments, there are barriers to these evaluations.
View Article and Find Full Text PDFPsychol Health Med
January 2025
Department of Physical Therapy, School of Health Sciences, Shinshu University, Matsumoto, Japan.
This systematic review and meta-analysis aimed to evaluate the effectiveness of psychological interventions compared to standard rehabilitation in patients with knee osteoarthritis (OA). Given the recognized influence of psychological factors in OA management, the review assessed their impact on pain, functional disability, and self-efficacy. A comprehensive search was performed across multiple databases, including PubMed, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials, Web of Science, OpenGrey, and ClinicalTrials.
View Article and Find Full Text PDFImplement Res Pract
January 2025
Department of Psychology, Temple University, Philadelphia, PA, USA.
Background: Dissemination initiatives have the potential to increase consumer knowledge of and engagement with evidence-based treatments (e.g., cognitive behavioral therapy [CBT]).
View Article and Find Full Text PDFWorld J Hepatol
January 2025
Medical Affairs, Tatvacare, Ahmedabad 380058, Gujarāt, India.
Background: Non-alcoholic fatty liver disease (NAFLD) management requires sustainable lifestyle modifications. This study aimed to evaluate the effectiveness of the RESET care plan, a comprehensive program that is an integrated personalized diet, exercise, and cognitive behavior therapy, delivered MyTatva's digital health application enabled through a body composition analyzer (BCA) and smartwatch.
Aim: To evaluates the effectiveness of the comprehensive program delivered MyTatva's digital health app enabled through internet of thing devices.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!